Pulmonary Arterial Hypertension in Patients with Primary Sjogren's Syndrome

Basit Öğe Kaydı
dc.authoridKOBAK, SENOL/0000-0001-8270-640X
dc.authoridErcan, Ertugrul/0000-0003-0480-4738
dc.contributor.authorKobak, Senol
dc.contributor.authorKalkan, Sezai
dc.contributor.authorKirilmaz, Bahadir
dc.contributor.authorOrman, Mehmet
dc.contributor.authorErcan, Ertugurul
dc.date.accessioned2025-01-27T20:22:41Z
dc.date.available2025-01-27T20:22:41Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction. Primary Sjogren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Doppler echocardiography is an important, noninvasive screening test for PAH diagnosis. Objective. The aim of this present study is to define the frequency of PAH in patients with pSS and to reveal correlations with laboratory and clinical findings. Material and Methods. A total of 47 patients, who were diagnosed with pSS according to American-European Study Group criteria were enrolled in the study. After all patients were evaluated clinically and by laboratory tests, Doppler echocardiography was performed in the cardiology outpatient clinic. Systolic pulmonary artery pressure (SPAP) >30 mm Hg values, which were measured at the resting state, were accepted as significant for PAH. Results. Forty-seven patients with pSS were included in the study. The mean age of patients was 48 years and the mean disease duration was 5.3 years. PAH was defined in 11 of the 47 patients (23.4%). The SPAP value was over 35 mm Hg in 5 out of 11 patients, whereas six patients had SPAP measuring 30-35 mm Hg. While pulmonary hypertension was related with earlier age and shorter duration of disease (p = 0.04), there was no statistically significant correlation between SPAP increase and clinical findings (p > 0.05). Conclusion. We have defined high PAH frequency in patients with pSS. Since there are different data in the literature, it is obvious that large scale, multicentre studies are required.
dc.identifier.doi10.1155/2014/710401
dc.identifier.issn2090-0422
dc.identifier.issn2090-0430
dc.identifier.pmid24511390
dc.identifier.scopus2-s2.0-84893190421
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1155/2014/710401
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21994
dc.identifier.volume2014
dc.identifier.wosWOS:000219161900026
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofAutoimmune Diseases
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectConnective-Tissue Disease
dc.subjectEchocardiographic-Assessment
dc.subjectEuropean-Association
dc.subjectSystemic-Sclerosis
dc.subjectAmerican-Society
dc.subjectRight Heart
dc.subjectGuidelines
dc.subjectClassification
dc.subjectSecondary
dc.subjectCriteria
dc.titlePulmonary Arterial Hypertension in Patients with Primary Sjogren's Syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu